European stocks rise as Novo Nordisk lifts healthcare on Wegovy data

Shares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison.

Leave a Comment

Your email address will not be published. Required fields are marked *

Invest Now
Scroll to Top
Open chat
Hello
Can we help you?